Cheung LWT - Search Results

1

Cancer-associated mutations in the p85α N-terminal SH2 domain activate a spectrum of receptor tyrosine kinases.

Li X, Lau AYT, Ng ASN, Aldehaiman A, Zhou Y, Ng PKS, Arold ST, Cheung LWT. Li X, et al. Among authors: cheung lwt. Proc Natl Acad Sci U S A. 2021 Sep 14;118(37):e2101751118. doi: 10.1073/pnas.2101751118. Proc Natl Acad Sci U S A. 2021. PMID: 34507989 Free PMC article.

2

Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.

Cheung LW, Yu S, Zhang D, Li J, Ng PK, Panupinthu N, Mitra S, Ju Z, Yu Q, Liang H, Hawke DH, Lu Y, Broaddus RR, Mills GB. Cheung LW, et al. Cancer Cell. 2014 Oct 13;26(4):479-94. doi: 10.1016/j.ccell.2014.08.017. Epub 2014 Oct 2. Cancer Cell. 2014. PMID: 25284480 Free PMC article.

3

Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium.

Cheung LW, Walkiewicz KW, Besong TM, Guo H, Hawke DH, Arold ST, Mills GB. Cheung LW, et al. Elife. 2015 Jul 29;4:e06866. doi: 10.7554/eLife.06866. Elife. 2015. PMID: 26222500 Free PMC article.

4

Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment.

Cheung LW, Mills GB. Cheung LW, et al. Pharmacogenomics. 2016 Feb;17(3):297-307. doi: 10.2217/pgs.15.174. Epub 2016 Jan 25. Pharmacogenomics. 2016. PMID: 26807692 Free PMC article. Review.

5

Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer.

Li X, Mak VCY, Zhou Y, Wang C, Wong ESY, Sharma R, Lu Y, Cheung ANY, Mills GB, Cheung LWT. Li X, et al. Among authors: cheung lwt, cheung any. Nat Commun. 2019 Feb 12;10(1):716. doi: 10.1038/s41467-019-08574-7. Nat Commun. 2019. PMID: 30755611 Free PMC article.

6

p85β regulates autophagic degradation of AXL to activate oncogenic signaling.

Rao L, Mak VCY, Zhou Y, Zhang D, Li X, Fung CCY, Sharma R, Gu C, Lu Y, Tipoe GL, Cheung ANY, Mills GB, Cheung LWT. Rao L, et al. Among authors: cheung lwt, cheung any. Nat Commun. 2020 May 8;11(1):2291. doi: 10.1038/s41467-020-16061-7. Nat Commun. 2020. PMID: 32385243 Free PMC article.

7

Strategic Combination Therapies for Ovarian Cancer.

Li X, Ng ASN, Mak VCY, Chan KKL, Cheung ANY, Cheung LWT. Li X, et al. Among authors: cheung lwt, cheung any. Curr Cancer Drug Targets. 2020;20(8):573-585. doi: 10.2174/1568009620666200511084007. Curr Cancer Drug Targets. 2020. PMID: 32392113 Review.

8

p85β alters response to EGFR inhibitor in ovarian cancer through p38 MAPK-mediated regulation of DNA repair.

Mak VC, Li X, Rao L, Zhou Y, Tsao SW, Cheung LW. Mak VC, et al. Neoplasia. 2021 Jul;23(7):718-730. doi: 10.1016/j.neo.2021.05.009. Epub 2021 Jun 16. Neoplasia. 2021. PMID: 34144267 Free PMC article.

9

AKTIP loss is enriched in ERα-positive breast cancer for tumorigenesis and confers endocrine resistance.

Ng ASN, Zhang S, Mak VCY, Zhou Y, Yuen Y, Sharma R, Lu Y, Zhuang G, Zhao W, Pang HH, Cheung LWT. Ng ASN, et al. Among authors: cheung lwt. Cell Rep. 2022 Dec 13;41(11):111821. doi: 10.1016/j.celrep.2022.111821. Cell Rep. 2022. PMID: 36516775 Free PMC article.

10

P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin.

Cheung LW, Mak AS, Cheung AN, Ngan HY, Leung PC, Wong AS. Cheung LW, et al. Oncogene. 2011 Jun 30;30(26):2964-74. doi: 10.1038/onc.2011.7. Epub 2011 Feb 14. Oncogene. 2011. PMID: 21317933

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

39 results

Search Page